Avino Silver & Gold Mines Ltd. ASM 深 沪
已收盘 12-12 16:00:00 美东时间
5.94
-0.220
-3.57%
华盛通- 最 高6.41
- 今 开6.37
- 成交量 590.82万股
- 最 低 5.78
- 昨 收 6.16
- 总市值 8.91亿
- 52周最高 6.665
- 市盈率 静 103.66
- 换手率 3.94%
- 52周最低 0.851
- 委 比 93.33%
- 总股本 1.50亿
- 历史最高 6.665
- 量 比 1.12
- 振 幅 10.23%
- 历史最低 0.255
- 每 手 1
- 风险率 1.53%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Micron, Endeavour Silver, First Majestic Silver, Applied Digital And Other Big Stocks Moving Higher On Friday
U.S. stocks were higher, with the Dow Jones gaining around 300 points on Friday...
11-29 00:19
Avino Silver & Gold Mines Renews $60M ATM Offering With Prospectus Supplements
Avino Silver & Gold Mines Ltd. (TSX:ASM)(NYSE:ASM)(FSE:GV6) ("Avino" or the "Company") announces that it has filed a prospectus supplement dated November 25, 2025 (the "Prospectus Supplement") to the Company's short
11-26 19:50
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 17:17
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 10:22
Earnings Scheduled For November 6, 2025
Companies Reporting Before The Bell • Clear Channel Outdoor (NYSE:CCO) is expec...
11-06 19:12
美股大行评级 | 高盛上调英伟达目标价升至240美元； Loop Capital上调英伟达目标价升至350美元！
今日重点评级关注：花旗：维持Caribou Biosciences"买入"评级，目标价从5美元升至8美元；HC Wainwright & Co.：上调MoonLake Immunotherapeutics - Class A Ordinary Shares评级至"买入"，目标价30美元
11-04 10:31
HC Wainwright & Co. Maintains Buy on Avino Silver & Gold Mines, Raises Price Target to $7.6
HC Wainwright & Co. analyst Heiko F. Ihle maintains Avino Silver & Gold Mines (AMEX:ASM) with a Buy and raises the price target from $6.1 to $7.6.
11-03 19:51
光大证券：维持ASMPT“增持”评级 TCB设备预计25Q4和2026年出货加速
光大证券发布研报称，维持ASMPT（00522）“增持”评级，AI需求强劲，主流业务和SMT恢复，TCB有望25Q4和2026年加速出货，但重组带来一次性费用...
10-30 16:30
ASM International Lowers FY2025 Sales Guidance from $3.824B to $3.772B
ASM International (OTC:ASMIY) lowers FY2025 sales outlook from $3.824 billion to $3.772 billion.
10-29 03:54
